Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690624 · ClinicalTrials.gov registry record · Phase 1
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01690624 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 30 participants.
The verdict
NCT01690624, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. In addition, acute myeloid leukemia patients who are in complete remission with high risk to relapse may be eligible for this trial. The trial will examine whether monotherapy with BI 836858 is safe and tolerable at escalating dose levels.
Interventions
- DRUG BI 836858
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-09-13 |
| Est. Completion | 2018-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01690624
The ClinicalTrials.gov registry entry for NCT01690624 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 836858 is the first listed.
NCT01690624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01690624 about?
NCT01690624 is a clinical study titled "BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse". Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. In addition, acute myeloid leukemia patients who are in complete remission with high risk to relapse may be eligible for this trial. The trial will examine whether monotherap...
What is the current status of trial NCT01690624?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-09-13. Estimated completion is 2018-05-21.
What interventions are being tested in trial NCT01690624?
The interventions under investigation include: BI 836858 (DRUG).
Who is sponsoring clinical trial NCT01690624?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.